**Main Tables**

*Table 1: Inclusion and Exclusion Criteria of Participating Studies*

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Study | Detailed Information of Each Study | Maternal age 16 - 50 yrs | Fetus without any congenital anomalies | No Indication for immediate delivery | Singleton pregnancy | Not attending antenatal care for the first time | Not participating in another trial affecting delivery timing or method | Give informed consent |
| Study 1  (Femina 1)2  N=305 | Setting: Manchester  Recruitment Period: 08.2009 - 10.2010  Prospective cohort | ✓ | ✓ | ✓ | ✓ | ✓ | Not mentioned | ✓ |
| Study 2  (Femina 2)5  N=296 | Setting: Manchester  Recruitment Period: 01.2012 - 05.2014  Prospective cohort | ✓ | ✓ | ✓ | ✓ | Not mentioned | Not mentioned | ✓ |
| Study 3  (Femina 3 – Manchester)  N=132 | Setting: Manchester  Recruitment Period: 10.2016 - 03.2017  Prospective cohort | ✓ | ✓ | ✓ | ✓ | Not mentioned | Not mentioned | ✓ |
| Study 4  (Femina 3 – Leicester)  N=107 | Setting: Leicester  Recruitment Period: 01.2020 - 04.2021 Prospective cohort | ✓ | ✓ | ✓ | ✓ | Not mentioned | Not mentioned | ✓ |
| Study 5  (Remit 1)4  N=119 | Setting: Manchester  Recruitment Period: 10.2011 - 08.2012  RCT | ✓ | ✓ | ✓ | ✓ | Not mentioned | Not mentioned | ✓ |
| Study 6  (Remit 2)36  N=216 | Setting: Multi-centre study (Six UK sites)  Recruitment Period: 03.2017 - 01.2018  RCT | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |

*Table 2: Outcome Counts in individual studies and total. NB Individual cases could have more than one adverse outcome, so the total adverse outcome count is greater than the composite measure (APO).*

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Outcome | Study 1 | Study 2 | Study 3 | Study 4 | Study 5 | Study 6 | APO by outcome |
| Stillbirth | 0 (0.0%) | 1 (0.3%) | 1 (0.8%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 2 (0.2%) |
| Fetal Growth Restriction (birthweight <3rd centile) | 26 (8.5%) | 13 (4.4%) | 1 (0.8%) | 9 (8.4%) | 1 (0.8%) | 4 (1.9%) | 54 (4.6%) |
| NICU admission (>37 wks’ gestation) | 2 (0.7%) | 9 (3%) | 6 (4.5%) | 6 (5.6%) | 4 (3.4%) | 11 (5.1%) | 38 (3.2%) |
| Total by study (individual outcomes) | 28 (9.2%) | 23 (7.8%) | 8 (6.1%) | 15 (14.0%) | 5 (4.2%) | 15 (6.9%) | 94 (8.0%) |
| Total by study (APO) | 28 (9.2%) | 22 (7.4%) | 7 (5.3%) | 14 (13.1%) | 5 (4.2%) | 14 (6.5%) | 90 (7.7%) |

*Table 3: Results of risk of bias assessment in individual studies*

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Table 3A: Results of risk of bias within each RCT using Cochrane Collaboration’s tool | | | | | | | | | | | | | | | | |
|  | | Selection bias | | | | Performance bias | | Detection bias | | Attrition bias | | | Reporting bias | | Other bias | |
| Heazell et al., 2013 | | low | | low | | high | | unclear | | low | | | low | | low | |
| Armstrong-Buisseret et al., 2020 | | low | | low | | high | | unclear | | low | | | low | | low | |
|  | | Random Sequence Generation | | Allocation Concealment | | Blinding of Participants and Personnel | | Blinding of Outcome Assessment | | Incomplete Outcome Data | | | Selective Reporting | | Other Bias | |
| \*Green - Low risk of bias; Red - High risk of bias; Blue – Unclear risk of bias. | | | | | | | | | | | | | | | | |
| Table 3B: Results of risk of bias within each prospective cohort study using Newcastle-Ottawa Scale (NOS) | | | | | | | | | | | | | | | | |
|  | Selection | | | | | | | | Comparability | | Outcome | | | | |  |
| Representativeness of the exposed cohort | | Selection of the non-exposed cohort | | Ascertainment of exposure | | Demonstration that outcome of interest was not present at start of study | | Comparability of cohorts on the basis of the design of analysis | | Assessment of outcome | Was follow-up long enough for outcomes to occur | | Adequacy of follow up of cohorts | | Final score |
| Dutton et al., 2012 | \* | | Not applicable | | \* | | \* | | \*\* | | \* | \* | |  | | 7 (Good) |
| Higgins et al., 2018 | \* | | Not applicable | | \* | | \* | | \*\* | | \* | \* | | \* | | 8 (Good) |
| Newcastle-Ottawa Scale (NOS) Criteria for Quality Assessment:   * **Good quality**: 3 or 4 stars in the selection domain AND 1 or 2 stars in the comparability domain AND 2 or 3 stars in the outcome/exposure domain. * **Fair quality**: 2 stars in the selection domain AND 1 or 2 stars in the comparability domain AND 2 or 3 stars in the outcome/exposure domain. * **Poor quality**: 0 or 1 star in the selection domain OR 0 stars in the comparability domain OR 0 or 1 stars in the outcome/exposure domain. | | | | | | | | | | | | | | | | |

*Table 4: IPD Meta-analysis results (log ORs, adjusted ORs, p-values, confidence intervals on OR scale, and the results of heterogeneity check) of risk factors on the Composite Adverse Pregnancy Outcome (Multivariate Analysis).*

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Risk Factor | Log-OR | Adjusted OR | P-Value | CI (OR scale) | Tau2 | I2 (%) | Q-statistic P-value | Egger test p-value |
| Maternal Age (years)\* | 0.0516 | 1.0529 | 0.0150 | (1.0100, 1.0976) | 0 | 0.00% | 0.5741 | 0.6249 |
| Gestation at RFM presentation (weeks) | -0.0637 | 0.9382 | 0.2308 | (0.8453, 1.0413) | 0.0063 | 41.58% | 0.1605 | 0.5946 |
| EFW percentile\* | -0.0273 | 0.9730 | 0.0040 | (0.9551, 0.9913) | 0.0004 | 76.84% | 0.0007 | 0.7634 |
| Past Medical History\* | 0.8238 | 2.2793 | 0.0314 | (1.0763, 4.8269) | 0.3843 | 46.08% | 0.0727 | 0.3874 |
| Cigarette Smoking\* | 0.9259 | 2.5241 | 0.0142 | (1.2045, 5.2895) | 0.2278 | 26.96% | 0.2410 | 0.8958 |